Similarly, reduced expression/activity of apoB in MR and six RCT studies resulted in genetically predicted lower levels of LDL cholesterol and total cholesterol in the UK Biobank as well as improved outcomes in the treatment of dyslipidaemias, respectively. Here, APOB is linked to inherited lipid metabolism disorder.